# Stelexis BioSciences

Source: https://onco.cc/companies/stelexis-biosciences/  
OnCo record `stelexis-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Stelexis BioSciences develops medicines for blood cancers that aim at the earliest faulty stem cells behind them. Its lead is a tablet that blocks an enzyme called PI3K-gamma, tested in acute myeloid leukaemia and higher-risk myelodysplastic syndromes.

## Summary

Stelexis BioSciences, of Waltham, Massachusetts, began as Stelexis Therapeutics, LLC, which Deerfield established in 2017 with scientific founders from Albert Einstein College of Medicine and Montefiore and from Boston Children's Hospital, and which closed a 43 million US dollar Series A in January 2019. It focuses on haematological cancers. Its lead, eganelisib, is a PI3K-gamma inhibitor in a phase 1 trial (NCT06533761) alone and with cytarabine in relapsed or refractory AML and higher-risk MDS, and with azacitidine in untreated higher-risk MDS, with sites in the US and Spain; the company announced positive phase 1 data in an oral presentation at ASCO 2026 and plans a first-line combination with azacitidine in PI3K-gamma high higher-risk MDS. An IL-1RAP programme, STLX-2012, is aimed at inflammatory disease. Its first registered cancer trial, NCT06533761, was posted on ClinicalTrials.gov in August 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Stelexis Therapeutics
- HQ: Waltham, MA
- Type: biotech
- Website: https://stelexis.com/

## Notes

- Founding year is from the January 2019 Series A release ('Deerfield established Stelexis in 2017'), linked from the company's own news page and read on 29 October 2026.
- Eganelisib was earlier developed by Infinity Pharmaceuticals; how Stelexis obtained it was not read.
- The ASCO 2026 data were described as positive by the company; the numbers were not read.

## Sources

- Official website: https://stelexis.com/
- Pipeline: https://stelexis.com/pipeline/
- Series A release, January 2019: https://www.prnewswire.com/news-releases/stelexis-therapeutics-closes-43-million-series-a-to-expand-novel-platform-focused-on-cancer-interception-300773175.html
- ClinicalTrials.gov: phase 1 trial of eganelisib (NCT06533761): https://clinicaltrials.gov/study/NCT06533761

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PI3K, AKT and mTOR inhibitors](https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/)
- targets: [PIK3CG](https://onco.cc/targets/pik3cg/)
- companies: [Deerfield Management](https://onco.cc/companies/deerfield-management/)

---
JSON: https://onco.cc/api/v1/entities/stelexis-biosciences.json